The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer

New England Journal of Medicine

Volumn 332, Issue 10, 1995, Pages 629-634

  Van Der Burg, Maria E l ^a   Van Lent, Mat ^a   Buyse, Marc ^a   Kobierska, Anna ^a   Colombo, Nicoletta ^a   Favalli, Giuseppe ^a   Lacave, Angel J ^a   Nardi, Mario ^a   Renard, Josette ^a   Pecorelli, Sergio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURGICAL APPROACH; SURGICAL TECHNIQUE; SURVIVAL RATE;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; OVARIECTOMY; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0028952438     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199503093321002     Document Type: Article

References (24)

1. Skipper HE Thoughts on cancer chemotherapy and combination modality therapy. JAMA 1974; 230: 1033-1035.
2. Goldie JH, Coldman AJ A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-1733.
3. Vogl SE, Pagano M, Kaplan BH, Greenwald E, Arseneau J, Bennett B Cis-platin based combination chemotherapy for advanced ovarian cancer: high overall response rate with curative potential only in women with small tumor burdens. Cancer 1983; 51: 2024-2030.
4. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, Long-term survival in ovarian cancer: mature data from the Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991; 27: 1367-1372.
5. Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1989; 7: 457-465
6. Eisenkop SM, Nalick RH, Wang HJ, Teng NN Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival. Gynecol Oncol 1993; 51: 224-229
7. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983; 61: 413-420
8. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992; 47: 159-166
9. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, Randomized trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 1984; 2: 594-600
10. Wils J, Blijham G, Naus A, Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 1986; 4: 1068-1073.
11. Potter ME, Partridge EE, Hatch KD, Soong SJ, Austin JM, Shingleton HM Primary surgical therapy of ovarian cancer: how much and when. Gynecol Oncol 1991; 40: 195-200
12. Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton J Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991; 42: 146-150
13. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987; 5: 1157-1168.
14. Kottmeier HL Presentation of therapeutic results in carcinoma of the female pelvis: experience of the annual report on the results of treatment in carcinoma of the uterus, vagina, and ovary. Gynecol Oncol 1976; 4: 13-19
15. World Health Organization. WHO handbook for reporting results of cancer treatments. World Health Organization offset publication no. 48. Geneva: World Health Organization, 1979.
16. George SL, Desu MM Planning the size and duration of a clinical trial studying the time to some critical event. J Chronic Dis 1974; 27: 15-24
17. Buyse M Interim analyses, stopping rules and data monitoring in clinical trials in Europe. Stat Med 1993; 12: 509-520
18. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
19. Peto R, Pike MC, Armitage P, Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39
20. Cox DR Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-220
21. Varma R, Redman CWE, Blackledge G, et al. Early second surgery in bulky epithelial ovarian cancer does not improve survival: results of a randomized study. In: Abstracts of the Second Meeting of the International Gynecologic Cancer Society, Toronto, October 9-13, 1989.
22. Lawton FG, Redman CWE, Luesley DM, Chan KK, Blackledge G Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet Gynecol 1989; 73: 61-65
23. Ng LW, Rubin SC, Hoskins WJ, Aggressive chemosurgical debulking in patients with advanced ovarian cancer. Gynecol Oncol 1990; 38: 358-363
24. Venesmaa P, Ylikorkala O Morbidity and mortality associated with primary and repeat operations for ovarian cancer. Obstet Gynecol 1992; 79: 168-172